Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gene therapy strategies for the treatment of chronic viral hepatitis
Autore:
Chiou, HC; Lucas, MA; Coffin, CC; Banaszczyk, MG; Ill, CR; Lollo, CP;
Indirizzi:
Immune Resp Corp, Carlsbad, CA 92008 USA Immune Resp Corp Carlsbad CA USA92008 Resp Corp, Carlsbad, CA 92008 USA
Titolo Testata:
EXPERT OPINION ON BIOLOGICAL THERAPY
fascicolo: 4, volume: 1, anno: 2001,
pagine: 629 - 639
SICI:
1471-2598(200107)1:4<629:GTSFTT>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOMINANT-NEGATIVE MUTANTS; DNA ENCODING IFN-ALPHA-1; IN-VIVO; VIRUS-INFECTION; DELIVERY SYSTEMS; TRANSGENIC MICE; HEMOPHILIA-B; PLASMID DNA; OLIGONUCLEOTIDE TRANSFER; INTRAMUSCULAR INJECTION;
Keywords:
antiviral agents; chronic viral hepatitis; drug carriers; gene therapy; gene transfer; IFN-alpha;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
81
Recensione:
Indirizzi per estratti:
Indirizzo: Chiou, HC Immune Resp Corp, 5939 Darwin Court, Carlsbad, CA 92008 USA Immune Resp Corp 5939 Darwin Court Carlsbad CA USA 92008 008 USA
Citazione:
H.C. Chiou et al., "Gene therapy strategies for the treatment of chronic viral hepatitis", EXPERT OP B, 1(4), 2001, pp. 629-639

Abstract

Chronic viral hepatitis is a major clinical problem, with over half a billion persons infected worldwide. Current therapies, principally treatment with recombinant IFN-a protein, have limited benefit. Recent studies suggest that gene-based expression of IFN-a is a possible therapeutic alternative that may improve the effectiveness of treatment. Gene delivery to the liver and consequent IFN-a expression therein, has the potential to concentrate the protein at the target organ and provide more continuous exposure to the therapeutic agent. Other potential gene and nucleic acid therapeutics for viral hepatitis are also being investigated. Key to the deployment of these future therapies is a suitable method of gene delivery. Although recombinant viral vector systems, such as adenovirus, are currently the most effective means of gene delivery to the liver, their use presents many concerns. These include immune and inflammatory reactions to the viral vector and possible adverse interactions between the recombinant virus and the pre-existingviral infection. Non-viral gene delivery systems would be a preferred treatment modality. The efficiency of current non-viral systems is not adequatefor systemically administered liver gene therapy. However, recent use of membrane permeabilisation techniques has shown that high efficiency non-viral gene transfer agents are possible. The future coupling of these improved delivery systems with gene- or nucleic acid-based therapeutics currently indevelopment holds out great promise for new generations of antihepatitis therapies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/02/20 alle ore 14:52:55